SCHEMBL1574941

SCHEMBL1574941

CC(C)CN(CC(C)C)C1CN(C(=O)Nc2ccccc2F)C1

nearest known ligand 0.60

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
KDM4E B2RXH2 1/20 0.60
LMNA P02545 2/20 0.47
RAB9A P51151 2/20 0.46
NPC1 O15118 1/20 0.46
HPGD P15428 1/20 0.43
GAA P10253 1/20 0.43
TAS1R3 Q7RTX0 1/20 0.42
TAS1R1 Q7RTX1 1/20 0.42
DDX3X O00571 1/20 0.42
NAMPT P43490 1/20 0.42
FAAH O00519 1/20 0.42
TRPV1 Q8NER1 1/20 0.42
EPHX2 P34913 1/20 0.41
HDAC1 Q13547 1/20 0.41
HDAC2 Q92769 1/20 0.41
TP53 P04637 1/20 0.41
KMT2A Q03164 1/20 0.41
L3MBTL1 Q9Y468 1/20 0.41
SMN1; SMN2 Q16637 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1575452 0.86 GAA (0.48) KDM4ELMNARAB9ANPC1GAA
SCHEMBL1574831 0.86 KDM4E (0.64) KDM4ERAB9ANPC1GAATAS1R3
SCHEMBL1574672 0.85 TAAR1 (0.50) KDM4ELMNATAS1R3TAS1R1TRPV1
SCHEMBL1575120 0.85 TAS1R3 (0.51) KDM4ELMNARAB9ANPC1HPGD
SCHEMBL1574518 0.84 KDM4E (0.61) KDM4ERAB9ANPC1GAATAS1R3
SCHEMBL1574995 0.84 KDM4E (0.64) KDM4ELMNARAB9ANPC1GAA
SCHEMBL1574969 0.83 KDM4E (0.54) KDM4ELMNAHPGDKMT2A
SCHEMBL1575289 0.82 KDM4E (0.59) KDM4ERAB9ANPC1GAATAS1R3
SCHEMBL1574846 0.82 NAMPT (0.50) KDM4ERAB9ANPC1HPGDNAMPT
SCHEMBL1575053 0.81 LMNA (0.55) KDM4ELMNARAB9ANPC1GAA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2308562-A2 Azetidine ring compounds and drugs comprising the same Ono Pharmaceutical Co., Ltd. (JP) 2011-04-13 EP disclosed
US-7511159-B2 Azetidine ring compounds and drugs comprising the same ONO PHARMACEUTICAL CO., LTD. (JP) 2009-03-31 US disclosed
US-20070135402-A1 Azetidine ring compounds and drugs comprising the same ONO PHARMACEUTICAL CO., LTD. (JP) 2007-06-14 US disclosed
EP-1698375-A1 AZETIDINE RING COMPOUNDS AND DRUGS COMPRISING THE SAME ONO PHARMACEUTICAL CO., LTD. (JP) 2006-09-06 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070135402-A1 Azetidine ring compounds and drugs comprising the same EDNRA, LIPG, EDNRB KDM4E 516/4885LMNA 1076/4885RAB9A 898/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.